Atea Pharmaceuticals (AVIR) Net Income towards Common Stockholders (2019 - 2026)

Atea Pharmaceuticals' Net Income towards Common Stockholders history runs 8 years deep, the most recent figure standing at -$45.4 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 32.59% year-over-year to -$45.4 million; the TTM figure through Mar 2026 stood at -$169.5 million (down 21.53% YoY), while the FY2025 annual figure was -$158.3 million, up 5.96% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$45.4 million, down from -$44.9 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$8.1 million in Q3 2022, with the low at -$63.2 million in Q1 2024.
• The 5-year median for Net Income towards Common Stockholders is -$35.5 million (2023), against an average of -$36.7 million.
• Peak annual rise in Net Income towards Common Stockholders reached 71.39% in 2022, while the deepest fall reached 2136.06% in 2022.
• Atea Pharmaceuticals' Net Income towards Common Stockholders stood at -$34.4 million in 2022, then fell by 13.75% to -$39.2 million in 2023, then gained by 14.35% to -$33.5 million in 2024, then sank by 33.76% to -$44.9 million in 2025, then retreated by 1.28% to -$45.4 million in 2026.
• Business Quant data shows AVIR's Net Income towards Common Stockholders at -$45.4 million in Q1 2026, -$44.9 million in Q4 2025, and -$42.0 million in Q3 2025.